Here is a summary of recent equity research hiring announcements.
Viktor Shvets joins Credit Suisse as a Managing Director and Head of Thematic Equity Research, Asia Pacific, based in Hong Kong, writing and co-ordinating research content that highlights the key investment themes and structural growth opportunities across Asia Pacific. In Singapore, Timothy Ross joins Credit Suisse as a Managing Director and Head of Asia Pacific Transport Research, Asia Pacific. Both hires were previously with Samsung Securities.
Software Analyst Joins MKM Partners
MKM Partners announced that Israel Hernandez has joined as a managing director in its equity research department. In his new role, Hernandez will cover software companies.
Software Analyst Joins Stifel Nicolaus
Brad Reback has joined Stifel Nicolaus as Managing Director and Senior Equity Research Analyst covering the Software Sector.
Renaissance Capital expands Asia equity research team
Renaissance Capital hires equity research analysts to cover oil and gas, and metals and mining.
Auriga Expands US Equity Research
The research group concentrates on equity research in the technology, consumer, industrial sectors, with a focus on healthcare with plans to expand each sector and sub-sector capabilities.
Nomura announces Global Equity & Quantitative Strategy
Michael will report jointly to Hideyuki Takahashi, Global Head of Research and Stewart Callaghan, Head of Equity Research AEJ. Nomura has also appointed Inigo Fraser-Jenkins as Global Head of Quantitative Strategy, based in London.
Wedbush Healthcare Analyst Joins Vital Therapies, Inc.
“We are delighted Dr. Nash is joining our program to commercialize ELAD in USA, EU and worldwide,” said Terry Winters, PhD, Vital Therapies, Inc.’s Chairman and Chief Executive Officer. “His unique mix of skills and experience in the life sciences will be invaluable in helping to transition the company to the public markets and in implementing our upcoming pivotal studies for marketing approval. His intimate knowledge of both clinical practice for liver disease and the breadth of new technologies under development is a compliment to the potential of ELAD in liver therapy.”
MLV Expands REIT Research Team
MLV & Co. announced today that Zachary Tanenbaum has joined the firm’s equity research team from FBR Capital Markets.